WO2009033812A3 - Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent - Google Patents
Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent Download PDFInfo
- Publication number
- WO2009033812A3 WO2009033812A3 PCT/EP2008/008156 EP2008008156W WO2009033812A3 WO 2009033812 A3 WO2009033812 A3 WO 2009033812A3 EP 2008008156 W EP2008008156 W EP 2008008156W WO 2009033812 A3 WO2009033812 A3 WO 2009033812A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- combination
- phe
- msh
- neuropeptide
- Prior art date
Links
- HWYCFZUSOBOBIN-AQJXLSMYSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminome Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 HWYCFZUSOBOBIN-AQJXLSMYSA-N 0.000 title abstract 2
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 title abstract 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 title abstract 2
- 102400001095 Neuropeptide FF Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is directed to the use of the combination of the peptide compounds Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 and Ac-Ser-Tyr-Ser-Met-Glu- His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017764 | 2007-09-11 | ||
| EP07017748 | 2007-09-11 | ||
| EP07017748.0 | 2007-09-11 | ||
| EP07017764.7 | 2007-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009033812A2 WO2009033812A2 (en) | 2009-03-19 |
| WO2009033812A3 true WO2009033812A3 (en) | 2009-05-22 |
Family
ID=40374301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/008156 WO2009033812A2 (en) | 2007-09-11 | 2008-09-09 | Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009033812A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110206642A1 (en) * | 2009-10-15 | 2011-08-25 | Cohava Gelber | Preventing obesity-related metabolic syndrome with melagonesis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000056353A2 (en) * | 1999-03-24 | 2000-09-28 | Zengen Inc. | A uro-genital condition treatment system |
| WO2001017958A2 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Neuropeptide sf receptor assays, compounds and therapeutic methods |
| WO2001082953A2 (en) * | 2000-05-02 | 2001-11-08 | Action Pharma Aps | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| WO2007067519A2 (en) * | 2005-12-06 | 2007-06-14 | Ophthalmic Research Associates, Inc. | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
-
2008
- 2008-09-09 WO PCT/EP2008/008156 patent/WO2009033812A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000056353A2 (en) * | 1999-03-24 | 2000-09-28 | Zengen Inc. | A uro-genital condition treatment system |
| WO2001017958A2 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Neuropeptide sf receptor assays, compounds and therapeutic methods |
| WO2001082953A2 (en) * | 2000-05-02 | 2001-11-08 | Action Pharma Aps | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| WO2007067519A2 (en) * | 2005-12-06 | 2007-06-14 | Ophthalmic Research Associates, Inc. | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009033812A2 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009033821A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043518A3 (en) | Use of a combination of cart peptides as a therapeutic agent | |
| WO2009043522A3 (en) | Use of a peptide as a therapeutic agent | |
| LTPA2017015I1 (en) | Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases | |
| EA201201400A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | |
| HK1126427A1 (en) | Low-dose rapamycin for the treatment of vascular permeability-related diseases | |
| IL184125A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| WO2007135026A3 (en) | Substituted pteridines as therapeutic agents | |
| WO2009033819A3 (en) | Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids | |
| WO2012061390A3 (en) | Therapeutic compositions and methods | |
| IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| WO2010094734A3 (en) | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation | |
| WO2009033813A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043525A3 (en) | Use of the combination of gluten exorphin c and cd36 as a therapeutic agent | |
| WO2009033818A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046875A3 (en) | Combination of splenopentin and thymopentin and the use thereof in medicine | |
| WO2009033814A3 (en) | Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent | |
| WO2010065563A3 (en) | Apratoxin therapeutic agents: mechanism and methods of treatment | |
| WO2008051421A3 (en) | Peptide-cytotoxic conjugates | |
| WO2009033816A3 (en) | Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent | |
| WO2009033820A3 (en) | Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis | |
| WO2009033809A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033812A3 (en) | Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent | |
| WO2009043519A3 (en) | Use of band 3 protein and pacap-27 as a therapeutic agent | |
| WO2008009426A9 (en) | 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802621 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08802621 Country of ref document: EP Kind code of ref document: A2 |